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Surgical ablationSurgical ablation of atrial ﬁbrillation (AF) is currently performed in many major hospitals throughout the world.
This paper reviews the development of surgical procedures for AF ablation. It is hoped that the paper can provide
a foundation for those involved with ablation of AF to improve patient care. AF is triggered by a rapidly ﬁring
focus and could be treatedwith a localized ablation procedure. A large body of literature has conﬁrmed the safety
and efﬁcacy of surgical ablation of AF. New ablation technologies have simpliﬁed the surgical treatment of AF and
expanded the indications. Generally, more extensive lesion sets have had better long-termoutcomes. Despite the
tremendous progress that has been made in the development of surgical ablation of AF, many questions remain
unanswered. It is anticipated that well designed clinical trials will continue to provide solid evidence to help for-
mulate practice guidelines in the future.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Deﬁnitions and mechanisms of atrial ﬁbrillation
Atrial ﬁbrillation (AF) is a common supraventricular arrhythmia
characterized by chaotic contraction of the atrium. Any arrhythmia
that has the electrocardiogram (ECG) characteristics of AF and lasts for
a 12-lead ECG recorded, or at least 30 s on a rhythmstrip, should be con-
sidered an AF episode [1,2].
For years, considerable progress has been made in deﬁning the
mechanisms of initiation and perpetuation of AF [3–5]. With the rec-
ognition that, in a subset of patients, AF was triggered by a rapidly
ﬁring focus and could be treated with a localized ablation procedure,
the arrhythmia community refocused its attention on the pulmonary
veins (PVs) and the posterior wall of the left atrium (LA), as well as
the autonomic innervation in that region. It also reinforced the con-
cept that the development of AF requires a trigger and an anatomic
or functional substrate capable of both initiation and perpetuation
of AF. Some authors [6–8] have proposed that, in the presence of an
appropriate heterogeneous AF substrate, a focal trigger can result
in sustained high frequency reentrant AF rotors. The waves thatParenthood Research, 277 Feng
a. Tel./fax: +86 25 86576012.
land Ltd. This is an open access articlemerge from the rotors undergo spatially distributed fragmentation
and give rise to ﬁbrillatory conduction. Sustained high rates in the
atrium and/or the presence of heart disease are associated with
structural remodeling of the atria and alter the substrate even fur-
ther and help to perpetuate AF [9–11].
2. Classiﬁcation of atrial ﬁbrillation
Although there are several classiﬁcation systems for AF, the classiﬁ-
cation system thatwas developed by the ACC/AHA/ESC 2006 Guidelines
for theManagement of Patientswith Atrial Fibrillation and the ESC 2010
Guidelines for the Management of Atrial Fibrillation [2,12,13] is recom-
mended here.
A patient who presents with AF for the ﬁrst time is considered to
have ﬁrst diagnosed AF, irrespective of the duration of the arrhythmia.
Paroxysmal AF is deﬁned as recurrent AF (≧ two episodes) that termi-
nates spontaneously within seven days. Persistent AF is deﬁned as
recurrent AF that is sustained for more than seven days. Patients with
continuous AF who undergo cardioversion within seven days should
be classiﬁed as having paroxysmal AF if the cardioversion is performed
within 48 h of AF onset, and persistent AF if the cardioversion is
performed more than 48 h after AF onset. Longstanding persistent AF
is deﬁned as continuous AF with duration of greater than one year. A
fourth category of AF is “permanent AF”. The term represents a joint
decision by the patient and a physician to cease further attempts to
restore and/or maintain sinus rhythm at a particular point in time. Ite under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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physician rather than any inherent pathophysiological attribute of the
AF. If after reevaluation, a rhythm control strategy is recommended,
the AF should then be redesignated as paroxysmal, persistent, or
longstanding persistent AF. Silent AF is deﬁned as asymptomatic AF
diagnosed by an opportune ECG or rhythm strip. A particular patient
may have AF episodes that fall into one or more of these categories. It
is recommended that patients be categorized by their most frequent
pattern of AF during the six months prior to performance of an ablation
procedure.
3. Surgical ablation of atrial ﬁbrillation
Although antiarrhythmic agents can be used for rhythm or rate
control, the medications are not universally effective, and chronic
requirement for medication and anticoagulation may also adversely af-
fect quality of life (QOL). A large body of literature, including multiple
prospective randomized clinical trials, has conﬁrmed the safety and
efﬁcacy of surgical ablation of AF [14]. In general, surgical ablation
procedures for AF can be grouped into three different groups: a full
Cox-maze procedure, pulmonary vein isolation (PVI) alone, and PVI
combined with left atrial lesion sets.
3.1. Cox-maze procedure
The Cox-maze procedure was ﬁrst introduced for the surgical
treatment of AF in 1987 by Dr. James Cox [15], with the intention of
eliminating AF by using incision scars to block the abnormal
electrical circuits. This procedure was designed to interrupt all
macroreentrant circuits that might potentially develop in the atria.
Fortuitously, the operation also isolated all of the PVs and the poste-
rior LA. The Cox-maze procedure successfully restored both atrio-
ventricular synchrony and sinus rhythm as well as decreased the
incidence of late stroke [16]. This effect was attributed to both AF
control and amputation of the LA appendage. The procedure in-
volved creating multiple strategically placed incisions across both
the right and left atria, which enabled the sinus node to direct the
propagation of the sinus impulse throughout both atria. It also
allowed most of the atrial myocardium to be activated, resulting in
the preservation of atrial transport function in most patients [17]. A
series of systematic improvements have subsequently been made,
culminating in the 1992 Cox-maze III procedure, which is now con-
sidered to be the “gold standard” for effective surgical treatment of
AF [18–20].
3.2. New surgical ablation technology
Despite its efﬁcacy, the Cox-maze procedure did not gain wide-
spread application. Few cardiac surgeons were willing to add the oper-
ation to coronary revascularization or valve procedures due to its
complexity, technical difﬁculty, and risks. In an attempt to simplify the
operation and make it more accessible to the average surgeon, groups
around the world replaced the incisions of the traditional cut-and-sew
Cox-maze procedure with linear lines of ablation. These ablation lines
are created using a variety of energy sources including radiofrequency
(RF) energy, cryoablation, microwave, and high intensity focused ultra-
sound (HIFU) [21,22]. The various technologies can be organized into
two major groups: those that use a unipolar energy source and those
that use a bipolar clamp.
The unipolar energy sources (cryoablation, unipolar RF energy,
HIFU) radiate either heat or cold from a single source. The unipolar
devices do not reliably provide the surgeon with an indication of
when the ablation results in a transmural lesion. Since most of these
ablation devices were released clinically without dose–response stud-
ies, their use has led to occasional collateral cardiac and extracardiac
damage [23,24]. Moreover, these energy sources have a ﬁxed depth ofpenetration, which may make their use in pathologically thickened
atria or from the epicardial surface on the beating heart problematic
[25–28].
Bipolar RF ablation has been able to overcome some of these
shortcomings [29–31]. Since energy is delivered between two close-
ly approximated electrodes embedded in the jaw of a clamp device,
the energy is focused and results in discrete lesions. The energy is
conﬁned to within the jaws of the clamp, reducing the possibility
of collateral cardiac or extracardiac damage. The weakness of these
devices is that they can only ablate tissue that can be clamped with-
in the jaws of the device. This has limited the potential lesion sets,
particularly in the beating heart. These devices have been incapable
of fully ablating the right and LA isthmus and have required adjunc-
tive unipolar ablation to perform a complete Cox-maze III lesion
set [32].
In spite of some deﬁciencies, the development of these new ablation
technologies has beneﬁted the surgical treatment of AF by making a
technically difﬁcult and time-consuming operation easier for general
cardiac surgeons to perform. Replicating the full Cox-maze lesion set
with linear lines of ablation has been shown to be both feasible and
clinically effective. A number of groups have reported excellent results
with ablation-assisted Cox-maze procedures [33–35].
3.3. Surgical atrialﬁbrillation ablation concomitant to other cardiac surgery
At present, more than 50% of the patients undergoing open-heart
surgery who have AF are offered concomitant AF surgery [36]. Prior AF
might place patients undergoing cardiac surgery at risk for early and
late mortality. Moreover, patients who have AF before cardiac surgery
have been shown to be generally older, haveworse ventricular function,
and other comorbidities [37–39]. AF may not be a speciﬁc marker for
high-risk patients, but itmay be an independent risk factor for increased
long term morbidity and mortality. Therefore, AF surgery may improve
survival or reduce late adverse cardiac events.
There have been several prospective randomized clinical trials of
surgical AF ablation performed in conjunction with other cardiac
surgical procedures [40–43]. A variety of left atrial lesion sets and ab-
lation tools were used in these trials including RF, microwave, and
cryoablation. In one study [41], 97 patients referred for mitral valve
surgery with six months or more of continuous AF were randomized
to receive mitral valve surgery and left atrial RF ablation (RFA) or mi-
tral valve surgery alone. At 12-month follow-up, sinus rhythm was
present in 44% of RFA patients and 4.5% of controls (p b 0.001). Res-
toration of sinus rhythm in the RFA group was accompanied by
greater improvement in mean shuttle-walk distance compared
with controls (p = 0.003). Patients randomized to receive RFA had
similar rates of post operative complications and deaths as control
patients.
More recent studies have documented success using a variety of dif-
ferent technologies, most commonly bipolar RF ablation, for the treat-
ment of AF with concomitant mitral or other cardiac operations
[44–47]. Success rates of these studies have varied between 65% and
95% at sixmonths. There has been great variation in the results between
different centers. This can be attributed to many factors, including sur-
geon experience, lesion sets, and the use of different ablation technolo-
gies. The type of lesion set has had the biggest impact on late results.
Generally, more extensive lesion sets have had better long-term out-
comes. The Cox-maze procedure and lesion sets created with alterna-
tive energy sources had a similar low prevalence of late post operative
AF. A largemeta-analysis of retrospective studies has also demonstrated
signiﬁcantly better late results with biatrial lesion sets when compared
to LA lesion sets alone [48].
The primary advantage of adding a full Cox-maze procedure to con-
comitant surgery, aside from the resumptionof sinus rhythm, is a reduc-
tion in the risk of stroke. For patients with a classic maze operation, the
risk of stroke at 10 years has been less than 1% in large published series
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atrial systole or due to closure or removal of the LA appendage or
continued use of warfarin in a subset of patients is not certain. The
stroke reduction from adding a Cox-maze procedure also applies
to patients who undergo mitral valve surgery, including replace-
ment with amechanical valve, which requires continued anticoagulation
with warfarin [49].
3.4. Stand-alone surgical ablation for atrial ﬁbrillation
There has been over two decades of experiencewith operations per-
formed solely for the treatment of AF when additional cardiac surgical
procedures are not performed. However, the complex surgical proce-
dure had a limited application in the treatment of patients with lone
AF. With the introduction of new ablation technology, there has been
renewed interest in less invasive procedures for stand-alone AF abla-
tion. When used in the open chest and a full biatrial Cox-maze lesion
set is performed, the procedure has been termed the Cox-maze IV
procedure.
The minimally invasive surgical approach using video-assisted
PV ablation and exclusion of the left atrial appendage was ﬁrst
described in 2005 [50]. A bipolar RF clamp was used for PVI on the
beating heart in 27 patients, among whom 18 had paroxysmal AF.
Among the 23 patients followed for more than three months, 21
(91%) were free of AF and 65% were off all antiarrhythmic drugs.
There were four major complications but no deaths and no pacemakers
were implanted. In a larger group of 74 patients [51], the strategy of
video-assisted bilateral PVI with conﬁrmation of block and partial auto-
nomic denervation was reported. At six months follow-up, 84% of
patients with paroxysmal AF were AF free and 57% of patients with
persistent or longstanding persistent AF were AF free. There was one
death, one hemothorax, one case of transient renal insufﬁciency, and
one patient with a transient brachial plexopathy. Another single-
center study experience with minimally invasive PVI and autonomic
ganglia ablation in 45 patients reported that 65% of patients were
free of recurrence of any atrial arrhythmia greater than 30 s in duration
at 12-month follow-up. There were no deaths; one phrenic nerve inju-
ry, and two pleural effusions [52].
The results of these and other trials cited earlier in this article have
made it clear that a more extensive lesion set than PVI alone is required
for successful surgical treatment of persistent and longstanding persis-
tent AF. The largest challenge to replicating the Cox-maze III lesion set
on the beating heart is making the connection to the mitral annulus.
The other connecting lesions can be done through the transverse
sinus.When connection lines to themitral annulus are added, however,
the success rates are shown to be comparable with the cut-and-sew
maze [53]. In traditional techniques, the connection to the mitral valve
is ablated across the left atrial isthmus. However, there are three inhib-
itors to doing this on the full beating heart. First, the traditional connec-
tion is to the posterior annulus, but visualization behind the full beating
heart's LA is very limited. Second, there is the risk of collateral damage
to the circumﬂex coronary artery overlying the mitral valve. Third, the
CS, which is used as the epicardial landmark for the mitral annulus, is
unreliable andmay leave a gap [54]. This leads to a signiﬁcant risk of in-
complete ablation or introducing atrial ﬂutter [55,56]. To address these
problems, the Dallas Lesion Set was developed [57]. The lesion set rep-
licates the left atrial lesions of the Cox-maze III. Results of a multicenter
registry including 124 patients showed less optimal safety assessment,
but outcomes remained relatively satisfactory [58]. Operative mortality
was 0.8%, and procedure-related major complications occurred in 10%
(renal failure, pericarditis, pneumothorax, pleural effusion, reoperation
for bleeding). After six months, sinus rhythm was achieved in 71% to
94%, depending on previous catheter ablation and measurement by
ECG or long-term monitoring. One-year success rate obtained by long-
term monitoring demonstrated a success rate of 63% in a group that
had previously undergone catheter ablation.3.5. Summary and indications
In summary, while surgery for AF has been performed for over
20 years, prospective multicenter clinical trials are needed to better de-
ﬁne the relative safety and efﬁcacy of various surgical tools and tech-
niques. It is critical for future studies to adopt consistent deﬁnitions of
procedural success and follow-up methodology, in order to compare
different surgical series and the surgical results to surgical ablation
[59]. Since the type and frequency of follow-up have varied widely be-
tween studies, the true success rates of these procedures are likely to
be lower than has been reported if more extensive monitoring is per-
formed in the future.
Even considering the shortcomings, the Cox-maze procedure has
had good long-term results when used as a stand-alone procedure or
when performed as a concomitant procedure in patients undergoing
other cardiac surgery. The advent of new ablation technologies has sim-
pliﬁed the surgical treatment of AF and expanded the indications, par-
ticularly for concomitant AF procedures in patients undergoing other
cardiac surgery.
Based on the results of clinical trials and clinical experience, it is
appropriate to consider all patients with symptomatic AF undergo-
ing other cardiac surgery for AF ablation. An LA procedure should
consist of PVI, ideally with a connecting lesion to the mitral valve
annulus. A biatrial procedure should be considered for those with
persistent and longstanding persistent AF. When it can be safely
performed, complete occlusion of the LA appendage should be
considered.
The referral of patients for surgery with symptomatic, medically
refractory AF in lieu of catheter ablation remains controversial.
There have been no head-to-head comparisons of the outcomes of
catheter and surgical ablation of AF. The decision-making in these
instances needs to be based on each institution's experience with
catheter and surgical ablation of AF, the relative outcomes and
risks of each in the individual patient, and patient preference. Fur-
thermore, it is well recognized that symptomatic and/or asymptom-
atic AF may recur during long-term follow-up after an AF ablation
procedure [60–62]. Therefore, post-ablation continuation of warfa-
rin or equivalent therapies is recommended in patients who have a
high stroke risk as determined by the CHADS2 or CHA2DS2VASc
score [63]. If anticoagulation withdrawal is being considered, addi-
tional ECG monitoring may be required, and a detailed discussion of
risk versus beneﬁt should be conducted.4. Conclusion
Surgical ablation of AF is a commonly performedprocedure through-
out the world. This paper provides a concise review of the history, tech-
niques, and outcomes of surgical ablation of AF. Despite the tremendous
progress that has been made in the development of surgical ablation of
AF,manyquestions remain unanswered. It is not yet possible to precise-
ly tailor an ablation strategy to a particular AF mechanism in the great
majority of AF patients. The long-term impact of surgical AF ablation
on major morbidity and mortality is also not currently available.Conﬂict of interest
The authors report no relationships that could be construed as a con-
ﬂict of interest.Acknowledgements
This workwas supported by theNational Nature Science Foundation
of China (No. 81270003, 81100826, 30901470).
10 Y. Zhang, L. Zhu / IJC Heart & Vessels 4 (2014) 7–11References
[1] Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJG, et al. HRS/EHRA/
ECAS expert consensus statement on catheter and surgical ablation of atrial ﬁbrilla-
tion: recommendations for personnel, policy, procedures and follow-up. A report of
the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of
Atrial Fibrillation developed in partnership with the European Heart Rhythm Asso-
ciation (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collabora-
tion with the American College of Cardiology (ACC), American Heart Association
(AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the
governing bodies of the American College of Cardiology, the American Heart Associ-
ation, the European Cardiac Arrhythmia Society, the European Heart Rhythm Asso-
ciation, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace
Jun. 2007;9(6):335–79.
[2] European Heart Rhythm Association, European Association for Cardio-Thoracic
Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, et al. Guidelines for the manage-
ment of atrial ﬁbrillation: the Task Force for the Management of Atrial Fibrillation of
the European Society of Cardiology (ESC). Europace Oct. 2010;12(10):1360–420.
[3] Haissaguerre M, Marcus FI, Fischer B, Clementy J. Radiofrequency catheter ablation
in unusual mechanisms of atrial ﬁbrillation: report of three cases. J Cardiovasc
Electrophysiol Sep. 1994;5(9):743–51.
[4] Jais P, HaissaguerreM, Shah DC, Chouairi S, Gencel L, HociniM, et al. A focal source of
atrial ﬁbrillation treated by discrete radiofrequency ablation. Circulation Feb. 4
1997;95(3):572–6.
[5] Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontane-
ous initiation of atrial ﬁbrillation by ectopic beats originating in the pulmonary
veins. N Engl J Med Sep. 3 1998;339(10):659–66.
[6] Berenfeld O, Mandapati R, Dixit S, Skanes AC, Chen J, Mansour M, et al. Spatially dis-
tributed dominant excitation frequencies reveal hidden organization in atrial ﬁbril-
lation in the Langendorff perfused sheep heart. J Cardiovasc Electrophysiol Aug.
2000;11(8):869–79.
[7] Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as
a mechanism of atrial ﬁbrillation in the isolated sheep heart. Circulation Jan. 18
2000;101(2):194–9.
[8] Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal period-
icity during atrial ﬁbrillation in the isolated sheep heart. Circulation Sep. 22
1998;98(12):1236–48.
[9] Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial ﬁbrillation: basic mechanisms, re-
modeling and triggers. J Interv Card Electrophysiol Sep. 2005;13(3):181–93.
[10] Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling
during atrial ﬁbrillation. Cardiovasc Res May 2002;54(2):230–46.
[11] Everett TH, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE, et al. Structural
atrial remodeling alters the substrate and spatiotemporal organization of atrial ﬁ-
brillation: a comparison in canine models of structural and electrical atrial remodel-
ing. Am J Physiol Heart Circ Physiol Dec. 2006;291(6):H2911–23.
[12] Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/
ESC 2006 guidelines for the management of patients with atrial ﬁbrillation-execu-
tive summary: a report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines and the European Society of Cardiology
Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guide-
lines for the Management of Patients with Atrial Fibrillation). Eur Heart J Aug.
2006;27(16):1979–2030.
[13] Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H-C, et al. Outcome param-
eters for trials in atrial ﬁbrillation: recommendations from a consensus conference
organized by the German Atrial Fibrillation Competence NETwork and the European
Heart Rhythm Association. Europace Nov. 2007;9(11):1006–23.
[14] Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for
atrial ﬁbrillation in cardiac surgery: a meta-analysis and systematic review. Innov
(Phila) Mar. 2010;5(2):84–96.
[15] Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, et al. The surgical
treatment of atrial ﬁbrillation. II. Intraoperative electrophysiologic mapping and de-
scription of the electrophysiologic basis of atrial ﬂutter and atrial ﬁbrillation. J Thorac
Cardiovasc Surg Mar. 1991;101(3):406–26.
[16] Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients
with atrial ﬁbrillation. J Thorac Cardiovasc Surg Nov. 1999;118(5):833–40.
[17] Feinberg MS, Waggoner AD, Kater KM, Cox JL, Lindsay BD, Perez JE. Restoration
of atrial function after the maze procedure for patients with atrial ﬁbrillation. As-
sessment by Doppler echocardiography. Circulation Nov. 1994;90(5 Pt 2):II285–92.
[18] McCarthy PM, Gillinov AM, Castle L, ChungM, Cosgrove III D. The Cox-maze procedure:
the Cleveland Clinic experience. Semin Thorac Cardiovasc Surg Jan. 2000;12(1):25–9.
[19] Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM, et al. The
Cox maze III procedure for atrial ﬁbrillation: long-term efﬁcacy in patients un-
dergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg Dec.
2003;126(6):1822–8.
[20] Schaff HV, Dearani JA, Daly RC, Orszulak TA, Danielson GK. Cox-maze procedure for
atrial ﬁbrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg Jan.
2000;12(1):30–7.
[21] Khargi K, Hutten BA, Lemke B, Deneke T. Surgical treatment of atrial ﬁbrillation; a
systematic review. Eur J Cardiothorac Surg Feb. 2005;27(2):258–65.
[22] Melby SJ, Lee AM, Damiano RJ. Advances in surgical ablation devices for atrial ﬁbril-
lation. In: Wang P, Naccarelli GV, Rosen MR, editors. New Arrhythmia Technologies.
Malden, MA: Blackwell Publishing, Inc.; 2005. p. 233–41.
[23] Demaria RG, Pagé P, Leung TK, Dubuc M, Malo O, Carrier M, et al. Surgical radiofre-
quency ablation induces coronary endothelial dysfunction in porcine coronary arter-
ies. Eur J Cardiothorac Surg Mar. 2003;23(3):277–82.[24] Laczkovics A, Khargi K, Deneke T. Esophageal perforation during left atrial radiofre-
quency ablation. J Thorac Cardiovasc Surg Dec. 2003;126(6):2119–20 [author reply
2120].
[25] Doll N, Kornherr P, Aupperle H, Fabricius AM, Kiaii B, Ullmann C, et al. Epicardial
treatment of atrial ﬁbrillation using cryoablation in an acute off-pump sheep
model. Thorac Cardiovasc Surg Oct. 2003;51(5):267–73.
[26] Santiago T, Melo J, Gouveia RH, Neves J, Abecasis M, Adragão P, et al. Epicardial ra-
diofrequency applications: in vitro and in vivo studies on human atrial myocardium.
Eur J Cardiothorac Surg Oct. 2003;24(4):481–6 [discussion 486].
[27] Thomas SP, Guy DJ, Boyd AC, Eipper VE, Ross DL, Chard RB. Comparison of epicardial
and endocardial linear ablation using handheld probes. Ann Thorac Surg Feb.
2003;75(2):543–8.
[28] Van Brakel TJ, Bolotin G, Salleng KJ, Nifong LW, Allessie MA, Chitwood WR, et al.
Evaluation of epicardial microwave ablation lesions: histology versus electro-
physiology. Ann Thorac Surg Oct. 2004;78(4):1397–402 [discussion 1397–
1402].
[29] Gaynor SL, Ishii Y, Diodato MD, Prasad SM, Barnett KM, Damiano NR, et al.
Successful performance of Cox-maze procedure on beating heart using bipo-
lar radiofrequency ablation: a feasibility study in animals. Ann Thorac Surg
Nov. 2004;78(5):1671–7.
[30] Khargi K, Deneke T, Haardt H, Lemke B, Grewe P, Müller KM, et al. Saline-irrigated,
cooled-tip radiofrequency ablation is an effective technique to perform the maze
procedure. Ann Thorac Surg Sep. 2001;72(3):S1090–5.
[31] Prasad SM,Maniar HS, DiodatoMD, Schuessler RB, Damiano Jr RJ. Physiological conse-
quences of bipolar radiofrequency energy on the atria and pulmonary veins: a chronic
animal study. Ann Thorac Surg Sep. 2003;76(3):836–41 [discussion 841–832].
[32] Ad N, Barnett S, Lefrak EA, Korach A, Pollak A, Gilon D, et al. Impact of follow-up on
the success rate of the cryosurgical maze procedure in patients with rheumatic heart
disease and enlarged atria. J Thorac Cardiovasc Surg May 2006;131(5):1073–9.
[33] Gammie JS, Laschinger JC, Brown JM, Poston RS, Pierson RN, Romar LG, et al. A multi-
institutional experience with the CryoMaze procedure. Ann Thorac Surg Sep.
2005;80(3):876–80 [discussion 880].
[34] Gaynor SL, Diodato MD, Prasad SM, Ishii Y, Schuessler RB, BaileyMS, et al. A prospec-
tive, single-center clinical trial of a modiﬁed Coxmaze procedurewith bipolar radio-
frequency ablation. J Thorac Cardiovasc Surg Oct. 2004;128(4):535–42.
[35] Weimar T, BaileyMS,Watanabe Y,Marin D,Maniar HS, Schuessler RB, et al. The Cox-
maze IV procedure for lone atrial ﬁbrillation: a single center experience in 100 con-
secutive patients. J Interv Card Electrophysiol Jun. 2011;31(1):47–54.
[36] Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB, O’Brien SM, et al.
Atrial ﬁbrillation correction surgery: lessons from the Society of Thoracic Surgeons
National Cardiac Database. Ann Thorac Surg Mar. 2008;85(3):909–14.
[37] Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W, et al. Inﬂuence
of atrial ﬁbrillation on outcome following mitral valve repair. Circulation Sep. 18
2001;104(12 Suppl. 1):I59–63.
[38] Ngaage DL, Schaff HV, Barnes SA, Sundt TM, Mullany CJ, Dearani JA, et al. Prognostic
implications of preoperative atrial ﬁbrillation in patients undergoing aortic valve re-
placement: is there an argument for concomitant arrhythmia surgery? Ann Thorac
Surg Oct. 2006;82(4):1392–9.
[39] Ngaage DL, Schaff HV, Mullany CJ, Sundt TM, Dearani JA, Barnes S, et al. Does preop-
erative atrial ﬁbrillation inﬂuence early and late outcomes of coronary artery bypass
grafting? J Thorac Cardiovasc Surg Jan. 2007;133(1):182–9.
[40] Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca M, et al. Ef-
fectiveness of the Maze procedure using cooled-tip radiofrequency ablation in pa-
tients with permanent atrial ﬁbrillation and rheumatic mitral valve disease.
Circulation Aug. 30 2005;112(9 Suppl.):I20–5.
[41] Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG, et al. Left atrial radiofre-
quency ablation during mitral valve surgery for continuous atrial ﬁbrillation: a ran-
domized controlled trial. Jama Nov. 9 2005;294(18):2323–9.
[42] Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazer H, Kilger E, et al. Surgical treat-
ment of permanent atrial ﬁbrillation using microwave energy ablation: a prospec-
tive randomized clinical trial. Eur J Cardiothorac Surg Oct. 2003;24(4):475–80
[discussion 480].
[43] Blomström-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S,
et al. A randomized double-blind study of epicardial left atrial cryoablation
for permanent atrial ﬁbrillation in patients undergoing mitral valve surgery:
the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J Dec.
2007;28(23):2902–8.
[44] Fayad G, Le Tourneau T, Modine T, Azzaoui R, Ennezat PV, Decoene C, et al. Endocar-
dial radiofrequency ablation during mitral valve surgery: effect on cardiac rhythm,
atrial size, and function. Ann Thorac Surg May 2005;79(5):1505–11.
[45] Gillinov AM, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson G, Sabik JF, et al.
Surgical ablation of atrial ﬁbrillation with bipolar radiofrequency as the primary mo-
dality. J Thorac Cardiovasc Surg Jun. 2005;129(6):1322–9.
[46] Halkos ME, Craver JM, Thourani VH, Kerendi F, Puskas JD, Cooper WA, et al. Intraop-
erative radiofrequency ablation for the treatment of atrial ﬁbrillation during con-
comitant cardiac surgery. Ann Thorac Surg Jul. 2005;80(1):210–5 [discussion 215–
216].
[47] Ninet J, Roques X, Seitelberger R, Deville C, Pomar JL, Robin J, et al. Surgical ablation
of atrial ﬁbrillation with off-pump, epicardial, high-intensity focused ultrasound: re-
sults of a multicenter trial. J Thorac Cardiovasc Surg Sep. 2005;130(3):803–9.
[48] Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial ﬁbrilla-
tion: a meta-analysis. J Thorac Cardiovasc Surg May 2006;131(5):1029–35.
[49] Bando K, Kasegawa H, Okada Y, Kobayashi J, Kada A, Shimokawa T, et al. Impact of
preoperative and postoperative atrial ﬁbrillation on outcome after mitral
valvuloplasty for nonischemic mitral regurgitation. J Thorac Cardiovasc Surg May
2005;129(5):1032–40.
11Y. Zhang, L. Zhu / IJC Heart & Vessels 4 (2014) 7–11[50] Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB, et al. Video-
assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for
atrial ﬁbrillation. J Thorac Cardiovasc Surg Sep. 2005;130(3):797–802.
[51] Edgerton JR, McClelland JH, Duke D, Gerdisch MW, Steinberg BM, Bronleewe SH,
et al. Minimally invasive surgical ablation of atrial ﬁbrillation: six-month results. J
Thorac Cardiovasc Surg Jul. 2009;138(1):109–13 [discussion 114].
[52] Han FT, Kasirajan V, Kowalski M, Kiser R, Wolfe L, Kalahasty G, et al. Results of a min-
imally invasive surgical pulmonary vein isolation and ganglionic plexi ablation for
atrial ﬁbrillation: single center experience with 12-month follow-up. Circ Arrhythm
Electrophysiol Aug. 2009;2(4):370–7.
[53] Jeanmart H, Casselman F, Beelen R, Wellens F, Bakir I, Van Praet F, et al. Modiﬁed
maze during endoscopic mitral valve surgery: the OLV Clinic experience. Ann Thorac
Surg Nov. 2006;82(5):1765–9.
[54] Shinbane JS, Lesh MD, Stevenson WG, Klitzner TS, Natterson PD, Wiener I, et al. An-
atomic and electrophysiologic relation between the coronary sinus and mitral annu-
lus: implications for ablation of left-sided accessory pathways. AmHeart J Jan. 1998-
9398;135(1).
[55] Antz M, Otomo K, Arruda M, Scherlag BJ, Pitha J, Tondo C, et al. Electrical conduction
between the right atrium and the left atrium via the musculature of the coronary
sinus. Circulation Oct. 27 1998;98(17):1790–5.
[56] Cox JL. Atrial ﬁbrillation II: rationale for surgical treatment. J Thorac Cardiovasc Surg
Dec. 2003;126(6):1693–9.[57] Edgerton JR, Jackman WM, Mack MJ. A new epicardial lesion set for minimal access
left atrial maze: the Dallas lesion set. Ann Thorac Surg Nov. 2009;88(5):1655–7.
[58] Edgerton JR, Jackman WM, Mahoney C, Mack MJ. Totally thorascopic surgical abla-
tion of persistent AF and long-standing persistent atrial ﬁbrillation using the “Dallas”
lesion set. Heart Rhythm Dec. 2009;6(12 Suppl.):S64–70.
[59] Shemin RJ, Cox JL, Gillinov AM, Blackstone EH, Bridges CR. Guidelines for reporting
data and outcomes for the surgical treatment of atrial ﬁbrillation. Ann Thorac Surg
Mar. 2007;83(3):1225–30.
[60] Kron J, Kasirajan V, Wood MA, Kowalski M, Han FT, Ellenbogen KA. Management of
recurrent atrial arrhythmias after minimally invasive surgical pulmonary vein isola-
tion and ganglionic plexi ablation for atrial ﬁbrillation. Heart Rhythm Apr.
2010;7(4):445–51.
[61] Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. Five-year outcomes after
segmental pulmonary vein isolation for paroxysmal atrial ﬁbrillation. Am J Cardiol
Aug. 1 2009;104(3):366–72.
[62] Wokhlu A, Hodge DO, Monahan KH, Asirvatham SJ, Friedman PA, Munger TM, et al.
Long-term outcome of atrial ﬁbrillation ablation: impact and predictors of very late
recurrence. J Cardiovasc Electrophysiol Oct. 2010;21(10):1071–8.
[63] Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation
of clinical classiﬁcation schemes for predicting stroke: results from the National Reg-
istry of Atrial Fibrillation. Jama Jun. 13 2001;285(22):2864–70.
